Anavex Life Sciences Corp.

6.35+0.0900+1.44%Vol 667.48K1Y Perf -42.52%
Oct 4th, 2023 16:00 DELAYED
BID6.10 ASK6.50
Open6.23 Previous Close6.26
Pre-Market- After-Market6.22
 - -  -0.13 -2.05%
Target Price
35.00 
Analyst Rating
Strong Buy 1.00
Potential %
451.18 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.79 
Earnings Rating
Strong Buy
Market Cap520.39M 
Earnings Date
27th Nov 2023
Alpha0.03 Standard Deviation0.24
Beta0.74 

Today's Price Range

6.176.40

52W Range

6.1015.24

5 Year PE Ratio Range

-13.50-10.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.08%
1 Month
-21.16%
3 Months
-21.85%
6 Months
-22.43%
1 Year
-42.52%
3 Years
56.11%
5 Years
151.41%
10 Years
152.42%

TickerPriceChg.Chg.%
AVXL6.350.09001.44
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.17-0.1417.65
Q02 2023-0.18-0.175.56
Q01 2023-0.20-0.1715.00
Q04 2022-0.16-0.18-12.50
Q03 2022-0.15-0.16-6.67
Q02 2022-0.16-0.1412.50
Q01 2022-0.16-0.1412.50
Q04 2021-0.13-0.15-15.38
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.165.88Positive
9/2023 FY-0.643.03Positive
12/2023 QR-0.1627.27Positive
9/2024 FY-0.62-44.19Negative
Next Report Date27th Nov 2023
Estimated EPS Next Report-0.16
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume667.48K
Shares Outstanding81.95K
Shares Float72.44M
Trades Count6.54K
Dollar Volume4.22M
Avg. Volume836.62K
Avg. Weekly Volume733.40K
Avg. Monthly Volume967.18K
Avg. Quarterly Volume809.29K

Anavex Life Sciences Corp. (NASDAQ: AVXL) stock closed at 6.26 per share at the end of the most recent trading day (a -1.57% change compared to the prior day closing price) with a volume of 834.13K shares and market capitalization of 520.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Anavex Life Sciences Corp. CEO is Christopher U. Missling.

The one-year performance of Anavex Life Sciences Corp. stock is -42.52%, while year-to-date (YTD) performance is -32.4%. AVXL stock has a five-year performance of 151.41%. Its 52-week range is between 6.095 and 15.24, which gives AVXL stock a 52-week price range ratio of 2.79%

Anavex Life Sciences Corp. currently has a PE ratio of -16.10, a price-to-book (PB) ratio of 5.47, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -33.13%, a ROC of -29.59% and a ROE of -35.51%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Anavex Life Sciences Corp., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Anavex Life Sciences Corp.’s next earnings report date is 27th Nov 2023.

The consensus rating of Wall Street analysts for Anavex Life Sciences Corp. is Strong Buy (1), with a target price of $35, which is +451.18% compared to the current price. The earnings rating for Anavex Life Sciences Corp. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anavex Life Sciences Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anavex Life Sciences Corp. has a Sell technical analysis rating based on Technical Indicators (ADX : 41.37, ATR14 : 0.35, CCI20 : -138.02, Chaikin Money Flow : -0.32, MACD : -0.42, Money Flow Index : 31.89, ROC : -17.31, RSI : 23.29, STOCH (14,3) : 7.19, STOCH RSI : 0.00, UO : 32.92, Williams %R : -92.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anavex Life Sciences Corp. in the last 12-months were: Christopher Missling (Option Excercise at a value of $800 000), Christopher Missling (Sold 268 000 shares of value $2 138 640 ), MISSLING CHRISTOPHER U (Option Exercise at a value of $800 000), MISSLING CHRISTOPHER U (Sold 268 000 shares of value $2 139 310 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

CEO: Christopher U. Missling

Telephone: +1 844 689-3939

Address: 51 West 52nd Street, New York 10019, NY, US

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

 

News

Stocktwits